| Literature DB >> 32010075 |
Xinzhu Wang1, Liya Zhao2, Chao Liu3, Jun Qi2, Peipei Zhao2, Zhaoming Liu4, Chunlei Li2, Yingying Hu1, Xin Yin2, Xin Liu2, Zhixin Liao1, Lixin Zhang2,5, Xuekui Xia2.
Abstract
Cycloaddition reactions such as intramolecular Diels-Alder (IMDA) are extremely important in constructing multicyclic scaffolds with diverse bioactivities. Using MycB as a biomarker, three new polyketides - Chaetolivacines A (1), B (3), and C (4) - with one known compound Myceliothermophin E (2) comprising of decalin and 4-hydroxy-2-pyridones were obtained from the culture of Chaetomium olivaceum SD-80A under the guidance of gene mining. The structures of these compounds were established using detailed 1D, 2D NMR, and high-resolution electron spray ionization mass spectroscopy (HRESIMS) analysis. The relative and absolute configurations of the compounds 1, 3, and 4 were elucidated by NOESY and ECD. The biosynthesis pathways of these compounds were proposed, which involves in three key genes ChaA [polyketide synthase-non-ribosomal peptide synthetases (PKS-NRPS)], ChaB, and ChaC. Compounds 1-4 were tested for their antimicrobial activities, and compounds 2 and 3 showed moderate bioactivity against Staphylococcus aureus (SA) and methicillin-resistant S. aureus (MRSA) with MIC values of 15.8 and 27.1 μM. The results showed that configuration of C-21 in 3 and 4 is important for anti-SA and anti-MRSA activities. This study reveals the significant potential of the genus Chaetomium in producing new PKS-NRPS, therefore increasing the speed in the mining for new sources of antimicrobial agents.Entities:
Keywords: Chaetomium olivaceum; anti-MRSA; biosynthesis pathway; isolation; tetramic acids
Year: 2020 PMID: 32010075 PMCID: PMC6974552 DOI: 10.3389/fmicb.2019.02958
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
The features of the Chaetomium olivaceum SD-80A genome.
| Sequencing technology | |
| Total size | 34,782,639 |
| Average G + C content | 55.57% |
| Scaffolds | 10658 |
FIGURE 1Comparison of Cha cluster and homologous gene cluster myc containing a PKS-NRPS hybrid, a DAse and a trans-ER. PKS-NRPS, polyketide synthase–non-ribosomal peptide synthetase; ER, enoylreductase; DAse, Diels–Alderases; MFS, major facilitator superfamily; α/β hydrotase, Alpha/beta hydrolase family.
FIGURE 2Sturctures of Compounds 1–4.
1H and 13C NMR data of 1 and 2 (δH in ppm, J in Hz).
| 1 | 136.3 | 5.37, s | 136.1 | 5.36, s |
| 2 | 130.2 | 131.7 | ||
| 3 | 51.1 | 3.23, d (7.2) | 51.0 | 3.23 d (7.2) |
| 4 | 49.7 | 3.89, dd (12, 7.2) | 49.6 | 4.04, dd (12, 7.2) |
| 5 | 40.0 | 1.86, td (12, 2) | 39.8 | 1.84, td (12, 2) |
| 6 | 24.3 | 0.98, m 1.69, m | 24.2 | 0.99, m 1.68, m |
| 7 | 35.8 | 0.98, m 1.70, m | 35.8 | 0.98, m 1.70, m |
| 8 | 27.5 | 1.69, m | 28.3 | 1.69, m |
| 9 | 48.6 | 0.95, m 1.47, m | 48.5 | 0.95, m 1.47, m |
| 10 | 35.2 | 35.3 | ||
| 11 | 22.8 | 0.90, s | 20.6 | 0.94, s |
| 12 | 20.6 | 0.86, d (6.0) | 22.8 | 0.86, d (6.0) |
| 13 | 22.2 | 1.48, s | 22.2 | 1.47, s |
| 14 | 135.9 | 135.9 | ||
| 15 | 123.4 | 5.08, d (6.8) | 123.2 | 5.08, d (6.8) |
| 16 | 13.3 | 1.43, s | 13.3 | 1.44, s |
| 17 | 14.0 | 1.46, s | 14.2 | 1.45, s |
| 18 | 196.6 | 197.1 | ||
| 19 | 134.8 | 134.8 | ||
| 20 | 143.9 | 7.61, d (2.0) | 142.0 | 7.44 d (2.0) |
| 21 | 134.2 | 134.0 | ||
| 23 | 169.8 | 170.3 | ||
| 24 | 119.5 | 6.34, s | 130.3 | 5.48, d (10.0) |
| 25 | 129.5 | 27.5 | 2.93, m | |
| 26,30 | 129.4 | 7.50, d (7.2) | 22.5 | 1.11, d (6.4) |
| 27,29 | 129.4 | 7.45, t (8.0) | 22.4 | 1.14, d (6.4) |
| 28 | 129.0 | 7.35, m | ||
| NH | 8.65, brs | 10.65, brs | ||
FIGURE 31H–1H COSY and Key HMBC correlations of 1.
FIGURE 4Key NOESY correlations of 1.
1H and 13C NMR data of 3 and 4 (δH in ppm, J in Hz).
| 1 | 136.4 | 5.35, brs | 136.4 | 5.35, brs |
| 2 | 136.3 | 136.3 | ||
| 3 | 51.0 | 3.17, d (7.2) | 51.0 | 3.06, d (7.6) |
| 4 | 50.9 | 3.80, dd (12.4, 7.6) | 51.0 | 3.83, dd (12.4, 7.6) |
| 5 | 39.9 | 1.81 (dt, covered) | 39.9 | 1.81 (dt, covered) |
| 6 | 24.2 | 1.62, m 0.94, m | 24.2 | 1.62, m 0.94, mF |
| 7 | 35.8 | 1.69, m 0.95, m | 35.7 | 1.69, m 0.95, m |
| 8 | 27.4 | 1.60, m | 27.4 | 1.60, m |
| 9 | 48.5 | 1.48, m 0.97, m | 48.5 | 1.48, m 0.97, m |
| 10 | 35.1 | 35.2 | ||
| 11 | 22.8 | 0.91, s | 20.5 | 0.91, s |
| 12 | 20.5 | 0.86, d (6.4) | 22.8 | 0.86, d (6.4) |
| 13 | 22.1 | 1.45, s | 22.1 | 1.45, s |
| 14 | 129.8 | 129.8 | ||
| 15 | 123.0 | 5.02, dd (6.4) | 123.1 | 5.07, dd (6.4) |
| 16 | 13.1 | 1.41, s | 13.3 | 1.41, s |
| 17 | 13.7 | 1.39, s | 13.7 | 1.39, s |
| 18 | 196.0 | 196.4 | ||
| 19 | 138.6 | 138.8 | ||
| 20 | 154.3 | 7.40, d (1.6) | 153.7 | 7.33, d (1.6) |
| 21 | 89.8 | 89.7 | ||
| 23 | 167.8 | 167.7 | ||
| 24- O-CH3 | 49.8 | 3.13, s | 49.9 | 3.13, s |
| 25 | 44.2 | 3.12 (d, 14.4) | 44.4 | 3.18 (d, 14) |
| 3.02 (d, 13.6) | 2.95 (d, 13.6) | |||
| 26 | 134.3 | 134.3 | ||
| 27,31 | 130.6 | 7.23 (m) | 130.5 | 7.23 (m) |
| 28,30 | 128.4 | 7.28 (m) | 128.5 | 7.28 (m) |
| 29 | 127.4 | 7.30 (m) | 127.4 | 7.30 (m) |
| NH | 6.02, brs | 5.86, brs | ||
FIGURE 5Key NOESY correlations of 3 and 4.
Antimicrobial activity of compounds 1–4.
| 1 | >100 | >100 | >100 | >100 | >100 | >100 |
| 2 | >100 | 15.8 | >100 | >100 | >100 | >100 |
| 3 | 10.8 | 27.1 | >100 | >100 | >100 | >100 |
| 4 | >100 | >100 | >100 | >100 | >100 | >100 |
FIGURE 6Proposed biosynthetic pathway for compound 1 based on isolated natural products and biochemical characterization of ChaB.